Exane Derivatives’s Colgate-Palmolive CL Stock Holding History

Exane Derivatives’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$721	Hold	9	–	–	﹤0.01%	537
2022 Q1	$682	Hold	9	–	–	﹤0.01%	838
2021 Q4	$768	Hold	9	–	–	﹤0.01%	734
2021 Q3	$680	Hold	9	–	–	﹤0.01%	905
2021 Q2	$744	Hold	9	–	–	﹤0.01%	905
2021 Q1	$710	Sell	9 -5,260	-100%	-$412K	﹤0.01%	762
2020 Q4	$451K	Buy	+5,269	New	+$436K	0.13%	182
2017 Q2	–	Sell	-1	Closed	-$73	–	637
2017 Q1	$73	Sell	1 -88,707	-100%	-$6.21M	﹤0.01%	506
2016 Q4	$5.8M	Sell	88,708 -23,752	-21%	-$1.63M	1.15%	11
2016 Q3	$8.34M	Sell	112,460 -18,692	-14%	-$1.38M	1.25%	17
2016 Q2	$9.6M	Sell	131,152 -26,998	-17%	-$1.92M	1.59%	31
2016 Q1	$11.2M	Buy	158,150 +157,983	+94,601%	+$10.5M	1.48%	33
2015 Q4	$11.1K	Hold	167	–	–	﹤0.01%	321
2015 Q3	$10.6K	Buy	167 +12	+8%	+$784	﹤0.01%	345
2015 Q2	$10.1K	Hold	155	–	–	﹤0.01%	362
2015 Q1	$10.7K	Buy	+155	New	+$10.7K	﹤0.01%	373

Other funds holding CL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Exane Derivatives's CL Position: Q2 2022 in Review

Exane Derivatives held its Colgate-Palmolive (CL) position steady in Q2 2022 at 9 shares worth $721. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Exane Derivatives first reported a position in CL in Q1 2015 and has held it in 16 quarters since. The position peaked at $11.2M in Q1 2016. 1,669 funds tracked by Wall St. Rank hold CL as of Q2 2022.

Exane Derivatives held 9 shares of Colgate-Palmolive worth $721 as of Q2 2022.
Exane Derivatives left its Colgate-Palmolive share count unchanged in Q2 2022.
Colgate-Palmolive made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #537 holding.
Exane Derivatives first reported a position in Colgate-Palmolive in Q1 2015 and has held it in 16 quarters since.
Exane Derivatives's Colgate-Palmolive position peaked at $11.2M in Q1 2016.
1,669 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.